Insmed surges after Q2 revenue beat
06/08/2026 12:27
BUZZ-Insmed surges after Q2 revenue beat ** Shares of drugmaker Insmed INSM.O rise 21% to $119.99 premarket
** Co's Q2 revenue of $425.5 million beats analysts' average expectation of $392.8 million, according to LSEG data
** Co expects annual revenue of $1.25 billion to $1.40 billion for its lung disease treatment Brinsupri, compared to its previous expectation of at least $1 billion
** The drugmaker reports Q2 sales of $309.2 million for Brinsupri, beating analysts' average expectation of $274.1 million
** Up to last close, stock down 43.1% YTD
(Reporting by Christy Santhosh)
Recent news on Insmed Incorporated
See all newsBrief: Insmed Launches Brinsupri® Tablets 25 Mg (Brensocatib Hydrate) For The Treatment Of Non-Cystic Fibrosis Bronchiectasis In Japan
Brief: Insmed Incorporated - Launches Four Pivotal Phase 3 Studies For TPIP In Pulmonary Diseases
U.S. STOCKS ON THE MOVE-Nike, Synopsys, Intel
Insmed CFO Sara Bonstein steps down; shares fall
U.S. STOCKS ON THE MOVE- Cenovus Energy, TeraWulf, Alector